Galapagos delivers candidate drug in GSK alliance and receives

Galapagos delivers candidate drug in GSK alliance and receives milestone payment  MECHELEN, BELGIUM -- (Marketwire) -- 01/09/13 -- Galapagos  NV (Euronext: GLPG) announced today  that it successfully delivered a fifth pre-clinical candidate drug in its alliance with GlaxoSmithKline (GSK) triggering a milestone payment to Galapagos.  In 2006 Galapagos and GSK initiated a drug discovery and development alliance to deliver  disease modifying  drugs for  GSK's global  R&D organization.   In this alliance Galapagos delivered a fifth candidate drug.  "Since  the  start  of  the  alliance  in  2006, Galapagos  has  identified five candidate  drugs of which two  have been in-licensed by  GSK to date," said Onno van de Stolpe, CEO of Galapagos.  "We hope that more programs from this alliance may enter the clinic."  About Galapagos' immuno-inflammation alliance with GlaxoSmithKline  Galapagos  and  GSK  initiated  an  alliance  to  discover  and develop disease-modifying  drugs for  GSK's global  R&D organization  in June 2006.  Subject to achievement  of certain milestone events Galapagos  has the potential to receive more  than EUR200  million in  total milestone  payments, plus  up to double-digit royalties  from  GSK.   GSK  has  an  exclusive  option  to  further develop and commercialize compounds from the alliance on a worldwide basis.  About Galapagos  Galapagos (Euronext: GLPG; OTC: GLPYY) is a mid-size clinical stage biotechnology company specialized in the discovery and development of small molecule and antibody therapies with novel modes-of-action.  The Company is progressing its JAK1 inhibitor GLPG0634, as well as one of the largest pipelines in biotech, with four programs in development and over 30 discovery programs. The Galapagos Group has over 800 employees and operates facilities in five countries, with global headquarters in Mechelen, Belgium.  More info at:  Galapagos forward-looking statements  This release may contain forward-looking statements, including, without limitation, statements containing the words "believes," "anticipates," "expects," "intends," "plans," "seeks," "estimates," "may," "will," "could," "stands to," and "continues," as well as similar expressions. Such forward-looking statements may involve known and unknown risks, uncertainties and other factors which might cause the actual results, financial condition, performance or achievements of Galapagos, or industry results, to be materially different from any historic or future results, financial conditions, performance or achievements expressed or implied by such forward-looking statements. Given these uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. These forward-looking statements speak only as of the date of publication of this document. Galapagos expressly disclaims any obligation to update any such forward-looking statements in this document to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based, unless required by law or regulation.  This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that:  (i) the releases contained herein are protected by copyright and     other applicable laws; and  (ii) they are solely responsible for the content, accuracy and      originality of the information contained therein.  Source: Galapagos NV via Thomson Reuters ONE  [HUG#1669132]  Contact  Galapagos NV Onno van de Stolpe CEO Tel: +31 6 2909 8028  Elizabeth Goodwin Director Investor Relations Tel: +31 6 2291 6240    
Press spacebar to pause and continue. Press esc to stop.